title: Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.
abstract: Alpha 1 antitrypsin deficiency (AATD) is a rare cause of chronic obstructive pulmonary disease. The lung disease is thought to be caused primarily by a lack of effective protection against the harmful effects of neutrophil elastase due to the low AAT levels in the lung. Patients may also develop liver disease due to polymerisation of AAT within hepatocytes. Consequently there has been much research over the years into AAT augmentation therapy in patients with lung disease, initially intravenously, and more recently in inhaled forms. This review article will discuss the role of augmentation therapy in AATD and the current status of recombinant AAT. The potential for other therapeutic strategies, such as blocking polymer formation, enhancing autophagy, gene therapy and stem cell-based treatment, will also be discussed more briefly.
authors.affiliation: QEHB Research Labs, University of Birmingham, Mindelsohn Way, Birmingham, B15 2WB, UK, a.m.wood@bham.ac.uk.
authors.forename: Alice M
authors.initials: AM
authors.lastname: Turner
mesh_terms: D000818:Animals; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D019272:Leukocyte Elastase / Q000378:metabolism; D008107:Liver Diseases / Q000209:etiology / Q000503:physiopathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D011994:Recombinant Proteins; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage / Q000627:therapeutic use*; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications / Q000503:physiopathology / Q000628:therapy*
chemical_list: D011994:Recombinant Proteins; D000515:alpha 1-Antitrypsin; D019272:Leukocyte Elastase